Cell Therapy Announces Positive Clinical Results

Cell Therapy Limited has presented their Phase II clinical trials data for their flagship product, Heartcel.

Trials were conducted on patients suffering from advanced heart failure, with 70% of them expected to die within a year. Following therapy with HeartCel, these patients now have:

  • A 30% improvement of their Left Ventricular Ejection Fraction (a measurement of the percentage of blood leaving your heart each time it contracts).
  • A 40% reduction in the size of the scar tissue found on the heart.
  • A 50% increase in quality of life

Despite the low life expectancy for these patients, 19-29 months on, they are all still alive and well and have not suffered any major adverse cardiac events.

The share price still has a way to go this year, with very encouraging Phase II data about their new TendonCel product being released in Q3 and the expectation that HeartCel will secure Breakthrough Therapy Designaton in Q4, there might be further positive share price news.

We expect this to be the last opportunity for angel investors to get involved and the closing date is imminent, if you, or anyone you know would like further information, please contact Simon Heywood on simon.heywood@ruffena.com.